John Paul de Koning
Director/Board Member presso ONWARD MEDICAL N.V.
Profilo
John Paul de Koning is currently a Director at eTheRNA immunotherapies NV, Onward Medical SA, Xylocor Therapeutics, Inc., Aelin Therapeutics NV, Xilis, Inc., Visus Therapeutics, Inc., Onward Medical NV, Coöperatief LSP IV UA, VarmX BV, and a Partner at EQT Life Sciences Group BV.
He previously held positions as a Non-Executive Director at Innovative Biosensors, Inc., argenx SE, and MyCartis NV, a Director at Prosensa Holding NV and Skyline Diagnostics BV, a Managing Director at Semaia Pharmaceuticals, and a Member-Supervisory Board at BMEYE BV and LSP Management Group BV.
He has also served as an Independent Non-Executive Director at Merus NV.
Dr. de Koning holds a doctorate from Erasmus University Rotterdam and a graduate degree from the University of Utrecht.
Posizioni attive di John Paul de Koning
Società | Posizione | Inizio |
---|---|---|
ONWARD MEDICAL N.V. | Director/Board Member | 01/01/2016 |
Xilis, Inc.
Xilis, Inc. Medical SpecialtiesHealth Technology Xilis, Inc. engages in the development of droplet-based microfluidics technology devices for precision cancer diagnostics and drug development. It offers Xilis platform. The company was founded by Xiling Shen and David Shu and is headquartered in Durham, NC. | Director/Board Member | 01/01/2018 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Director/Board Member | 01/01/2021 |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Director/Board Member | 01/01/2020 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Director/Board Member | - |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Director/Board Member | - |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Director/Board Member | 01/01/2016 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Director/Board Member | 01/03/2016 |
Coöperatief LSP IV UA | Director/Board Member | 01/01/2010 |
░░░ ░░░░ ░░░░░░░░ ░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Precedenti posizioni note di John Paul de Koning
Società | Posizione | Fine |
---|---|---|
░░░ ░░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di John Paul de Koning
Erasmus University Rotterdam | Doctorate Degree |
University of Utrecht | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
MERUS N.V. | Health Technology |
ARGENX SE | Health Technology |
ONWARD MEDICAL N.V. | Commercial Services |
Aziende private | 16 |
---|---|
Innovative Biosensors, Inc.
Innovative Biosensors, Inc. Medical SpecialtiesHealth Technology Innovative Biosensors, Inc. develops, manufactures and markets pathogen detection and diagnostic systems. Its systems comprises of biosensors that generate results at previously unseen levels of sensitivity and specificity. The firm also offers bioflash-dx, a diagnostics platform for the testing of infectious and other human diseases. The company was founded by Joe Hernandez in 2003 and is headquartered in Rockville, MD. | Health Technology |
BMEYE BV
BMEYE BV Electronic Equipment/InstrumentsElectronic Technology BMEYE BV operates as a non-invasive cardiovascular monitoring company. The firm manufactures and distributes non-invasive technology, hemodynamic monitoring equipment and related medical devices. It offers finger arterial pressure and cardiac output technologies. The company was founded in April 2005 and is headquartered in Amsterdam, the Netherlands. | Electronic Technology |
Coöperatief LSP IV UA | Finance |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Finance |
MyCartis NV
MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
Prosensa Holding NV
Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Skyline Diagnostics BV
Skyline Diagnostics BV Electronic Equipment/InstrumentsElectronic Technology Skyline Diagnostics develops and commercializes diagnostic microarrays for oncology. These tests currently provide the healthcare professional diagnostic information using one comprehensive test and may be useful in the clinical management of patients with cancer. Skyline Diagnostics products are currently available research only tools in the United States. The development pipeline includes diagnostic tests for Acute Myeloid Leukemia, Multiple Myeloma, Acute Lymphatic Leukemia, and Brain tumors. | Electronic Technology |
Semaia Pharmaceuticals | |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Health Technology |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |
Xilis, Inc.
Xilis, Inc. Medical SpecialtiesHealth Technology Xilis, Inc. engages in the development of droplet-based microfluidics technology devices for precision cancer diagnostics and drug development. It offers Xilis platform. The company was founded by Xiling Shen and David Shu and is headquartered in Durham, NC. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Finance |
- Borsa valori
- Insiders
- John Paul de Koning